Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2004 1
2009 1
2013 7
2014 20
2015 4
2016 2
2017 3
2018 5
2019 1
2020 3
2021 2
2022 6
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Regional, circuit and network heterogeneity of brain abnormalities in psychiatric disorders.
Segal A, Parkes L, Aquino K, Kia SM, Wolfers T, Franke B, Hoogman M, Beckmann CF, Westlye LT, Andreassen OA, Zalesky A, Harrison BJ, Davey CG, Soriano-Mas C, Cardoner N, Tiego J, Yücel M, Braganza L, Suo C, Berk M, Cotton S, Bellgrove MA, Marquand AF, Fornito A. Segal A, et al. Nat Neurosci. 2023 Sep;26(9):1613-1629. doi: 10.1038/s41593-023-01404-6. Epub 2023 Aug 14. Nat Neurosci. 2023. PMID: 37580620 Free PMC article.
Relationship of HLA-B alleles on susceptibility to and protection from HIV infection in Turkish population.
Darbas S, Inan D, Kilinc Y, Arslan HS, Ucar F, Boylubay O, Koksoy S, Mutlu E, Yucel B, Ekinci NS. Darbas S, et al. North Clin Istanb. 2022 Dec 13;10(1):67-73. doi: 10.14744/nci.2021.00018. eCollection 2023. North Clin Istanb. 2022. PMID: 36910436 Free PMC article.
METHODS: This retrospective case-control study consisted of 416 (F/M:111/305) HIV positive patients and 416 (F/M:111/305) healthy controls. ...CONCLUSION: Our results suggest that, HLA-B*07, *14, and *55 alleles and HLA-B*07:02, *14:01, *44:01, and *55 …
METHODS: This retrospective case-control study consisted of 416 (F/M:111/305) HIV positive patients and 416 (F/M:111/305) heal …
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
Dal MS, Ulu BU, Uzay A, Akay OM, Beşışık S, Yenerel MN, Çelik S, Kaynar L, Yücel OK, Deveci B, Sönmez M, Mehtap Ö, Beköz HS, Sunu C, Salim O, Ulaş T, Kartı S, Altuntaş F, Ferhanoğlu B, Tuğlular TF. Dal MS, et al. Ann Hematol. 2023 Jan;102(1):133-140. doi: 10.1007/s00277-022-05052-x. Epub 2022 Nov 19. Ann Hematol. 2023. PMID: 36401621 Free PMC article.
Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient pro …
Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse la …
Choroidal Thickness in Strabismus and Amblyopia Cases.
Niyaz L, Yücel OE, Arıtürk N, Terzi O. Niyaz L, et al. Strabismus. 2017 Jun;25(2):56-59. doi: 10.1080/09273972.2017.1318152. Epub 2017 May 2. Strabismus. 2017. PMID: 28463529
RESULTS: The mean subfoveal choroidal thickness in the control and hypermetropia groups was 323.969.0 m and 348.964.5 m, respectively. Mean choroidal thickness in amblyopic and fellow eyes was 387.4 and 351.9 m in anisometropic, 353.8 and 338.7 m in ex …
RESULTS: The mean subfoveal choroidal thickness in the control and hypermetropia groups was 323.969.0 m and 348.964.5 m, respe …
Consensus statement: Long-term results of ABI in children with complex inner ear malformations and decision making between CI and ABI.
Sennaroğlu L, Colletti V, Lenarz T, Manrique M, Laszig R, Rask-Andersen H, Göksu N, Offeciers E, Saeed S, Behr R, Bayazıt Y, Casselman J, Freeman S, Kileny P, Lee DJ, Shannon RV, Kameswaran M, Hagr A, Zarowski A, Schwartz MS, Bilginer B, Kishore A, Sennaroğlu G, Yücel E, Saraç S, Ataş A, Colletti L, O'Driscoll M, Moon IS, Gärtner L, Huarte A, Nyberg G, Mocan BÖ, Atay G, Bajin MD, Çınar BÇ, Batuk MÖ, Yaralı M, Aydınlı FE, Aslan F, Kirazlı MC, Özkan HB, Hans JM, Kosaner J, Polak M. Sennaroğlu L, et al. Cochlear Implants Int. 2016 Jul;17(4):163-171. doi: 10.1080/14670100.2016.1208396. Epub 2016 Jul 21. Cochlear Implants Int. 2016. PMID: 27442073 No abstract available.
Determination and pharmacokinetic study of riociguat by UPLC-MS/MS in human plasma.
Kocak OF, Albayrak M, Yaman ME, Atila A, Kadioglu Y, Araz O. Kocak OF, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Nov 1;1210:123454. doi: 10.1016/j.jchromb.2022.123454. Epub 2022 Sep 7. J Chromatogr B Analyt Technol Biomed Life Sci. 2022. PMID: 36095936
Riociguat and irbesartan (IS) were detected using ESI in positive ion and multiple reaction monitoring mode, respectively, by monitoring the mass transitions m/z 423.0 391.0 and 429.1 206.9. A reverse-phase C18 column (5 mum, 4.6 150 mm) was used with an isocratic mobile p …
Riociguat and irbesartan (IS) were detected using ESI in positive ion and multiple reaction monitoring mode, respectively, by monitoring the …
59 results